-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mymetics and PCI Biotech Sign a Preclinical Research Collaboration
Mymetics and PCI Biotech Sign a Preclinical Research Collaboration
EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of cancer therapy.
The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline under development, among which are the Covid-19, HIV-1/AIDS and malaria, and collaborative projects in the cancer immunotherapy.
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. Virosomes have shown to trigger also specific T-cell responses. For further information, please visit .
For further information, please contact:
Ronald Kempers, CEO
email: info@mymetics.com
+41 21 653 4535
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
SOURCE: Mymetics Corporation
View source version on accesswire.com:
EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of cancer therapy.
瑞士埃帕林吉斯/ACCESSWIRE/2022年8月31日/Mymetics Corporation(OTCQB:MYMX)与挪威专注于癌症的生物制药公司PCI Biotech(OSE:PCIB)达成临床前研究合作,旨在探索可能增强癌症治疗的技术协同效应。
The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.
该项目是确定Mymetics和PCI Biotech之间是否有进一步合作的基础的第一步,合作持续时间短,对涉及的任何一方都不会立即产生商业影响。
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline under development, among which are the Covid-19, HIV-1/AIDS and malaria, and collaborative projects in the cancer immunotherapy.
关于Mymetics
Mymetics Corporation(场外交易市场代码:MYMX)是一家总部设在瑞士的生物技术公司,在荷兰设有研究实验室,专注于为传染病和致人死亡的疾病开发下一代预防性疫苗。目前,中国正在研发几种疫苗,其中包括新冠肺炎、艾滋病毒/艾滋病和疟疾,以及癌症免疫治疗方面的合作项目。
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. Virosomes have shown to trigger also specific T-cell responses. For further information, please visit .
Mymetics的核心技术和专长是使用病毒体,即含有功能性融合病毒蛋白和天然膜蛋白的脂基载体,与合理设计的抗原相结合。该公司的疫苗旨在诱导对早期传播和感染的保护,重点是粘膜和血清免疫反应。病毒体已经被证明也能触发特定的T细胞反应。欲了解更多信息,请访问。
For further information, please contact:
如需更多信息,请联系:
Ronald Kempers, CEO
email: info@mymetics.com
+41 21 653 4535
罗纳德·肯珀斯,首席执行官
电子邮件:info@mymetics.com
+41 21 653 4535
Forward looking statements
前瞻性陈述
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
1995年的私人证券诉讼改革法为前瞻性陈述提供了“安全港”,这些前瞻性陈述由“相信”、“预期”、“预期”、“打算”、“计划”和类似的表述来识别。本文中包含的非基于历史事实的陈述为前瞻性陈述,涉及已知和未知的风险和不确定性,这些风险和不确定性可能会对我们未来的实际结果、业绩或成就产生重大影响,因此,该等实际结果、业绩或成就可能与我们或代表我们所作的任何前瞻性陈述中明示或暗示的内容存在实质性差异。这些风险和不确定性包括但不限于与我们成功开发和保护我们的知识产权的能力、我们筹集额外资本为未来运营提供资金的能力以及遵守适用法律和此类法律的变化以及此类法律的管理相关的风险。有关此类风险、不确定性和其他因素的讨论,请参阅Mymetics最新的Form 10-K。告诫读者不要过度依赖这些前瞻性声明,这些声明只反映了声明发表之日的情况。
SOURCE: Mymetics Corporation
资料来源:Mymetics公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧